GSK’s Blenrep combination approved in Singapore for treatment of relapsed/refractory Multiple myeloma

CAR-T Digest - August 2020

Weekly Digest - August 2026

19 August 2026: GSK’s Blenrep combination approved in Singapore for treatment of relapsed/refractory Multiple myeloma

GSK announced that Singapore’s Health Sciences Authority has approved Blenrep in combination with bortezomib plus dexamethasone for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy, and with pomalidomide plus dexamethasone for patients who have received at least one prior therapy including lenalidomide
The approval are supported by the phase 3 DREAMM-7 and DREAMM-8 trials, where Blenrep combinations significantly improved progression-free survival versus standard-of-care triplets; in DREAMM-7, median PFS was 36.6 vs. 13.4 months (HR=0.41) and the combination reduced the risk of death by 42% (OS HR=0.58), while in DREAMM-8, median PFS was not reached vs. 12.7 months with the comparator at the primary analysis with median follow-up of 21.8 months
The approval address a significant unmet need in relapsed or refractory multiple myeloma, where most patients eventually experience disease relapse and require additional treatment options that can extend remission and survival while maintaining manageable tolerability
Blenrep is a BCMA-targeted ADC comprising a humanized anti-BCMA monoclonal antibody conjugated to the cytotoxic auristatin F payload through a non-cleavable linker, enabling targeted delivery of the payload to BCMA-expressing myeloma cells
Strategically, the Singapore approvals strengthen Blenrep’s position in the relapsed/refractory multiple myeloma landscape, expanding its use across multiple combination regimens while further broadening the regional availability of GSK’s BCMA-targeted ADC in Asia and supporting the continued expansion of Blenrep into additional international markets